Patents Assigned to Merck
  • INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2
    Publication number: 20190330239
    Abstract: The present invention relates to a compound represented by formula I?: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 31, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Thomas H. Graham, Wensheng Liu, Clare Tudge, Andreas Verras, Jinlong Jiang
  • ?-alumina flakes
    Patent number: 10457812
    Abstract: Alpha-Alumina flakes having a particle thickness of 550-1000 nm, a D50-value of 15-30 ?m, a D90-value of 30-45 ?m and a D10-value of ?9.0 ?m. Use of the alumina flakes in varnishes, paints, automotive coatings printing inks, masterbatches, plastics and cosmetic formulations. Also, use of the alumina flakes as a substrate for effect pigments and in organic dyes.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ryuta Suzuki, Gerhard Pfaff, Sabine Schoen, Fumiko Sasaki, Satoru Kobayashi, Koshiro Kunii, Yuji Takenaka, Katsuhisa Nitta
  • Robust antibody purification
    Patent number: 10457720
    Abstract: The present invention refers to a method for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Romas Skudas, Matthias Joehnck, Bianca Edelmann, Simon Braun, Mikhail Kozlov, Matthew T. Stone, Kevin Galipeau
  • Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
    Patent number: 10457677
    Abstract: Compounds of the formula (I), which are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Compounds for optically active devices
    Patent number: 10457658
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub
  • Process for preparing substituted tetracyclic heterocycle compounds
    Patent number: 10457690
    Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
  • Compounds and liquid-crystalline medium
    Patent number: 10457871
    Abstract: Compounds of formula I, in which X1, X2, Sp, and R are as defined herein, are suitable for use in liquid-crystal media, such as liquid-crystal media used in liquid-crystal displays.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: October 29, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Achim Goetz, Rocco Fortte, Martin Engel, Sabrina Maag, Ingo Almeroth, Thomas Mergner, Thorsten Kodek, Detlef Pauluth
  • ALPHA-ALUMINA FLAKES
    Publication number: 20190322871
    Abstract: The present invention relates to alumina flakes having a defined thickness and particle size distribution and to their use in varnishes, paints, automotive coatings printing inks, masterbatches, plastics and cosmetic formulations and as substrate for effect pigments. and organic dyes.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicant: Merck Patent GmbH
    Inventors: Ryuta SUZUKI, Gerhard PFAFF, Sabine SCHOEN, Fumiko SASAKI, Satoru KOBAYASHI, Koshiro KUNII, Yuji TAKENAKA, Katsuhisa NITTA
  • MATERIALS FOR ELECTRONIC DEVICES
    Publication number: 20190322796
    Abstract: The present application relates to a polymer containing at least one structural unit of a formula (I) and at least one further structural unit selected from structural units A, B and C. The present application further relates to the use of the polymer in an electronic device and to a process for preparing the polymer. The present application further relates to an electronic device comprising the polymer.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 24, 2019
    Applicant: Merck Patent GmbH
    Inventors: Beate Burkhart, Katja Maria Scheible, Nils Koenen, Holger Heil
  • FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
    Publication number: 20190322666
    Abstract: The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 24, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, Sherman T. Waddell, Thomas H. Graham, Yonglian Zhang, John A. McCauley, Andrew W. Stamford, Jiaqiang Cai, Zhiqi Qi
  • FLUORINE CONTAINING POLYMERS
    Publication number: 20190322776
    Abstract: The present invention relates to novel fluorine containing polymers, compositions comprising the polymers, the use of the polymers in coatings, especially in water and dirt repellent coatings, and products coated with polymer containing coatings.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 24, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Haibo FANG, Reiner FRIEDRICH
  • ANTIVIRAL BENZYL-AMINE PHOSPHODIAMIDE COMPOUNDS
    Publication number: 20190321380
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Manuel de Lera Ruiz, Timothy J. Hartingh, Izzat Raheem, John Schreier, Jean-Laurent Paparin
  • Antiviral prodrugs of tenofovir
    Patent number: 10449208
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 22, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.
    Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
  • Bimesogenic compounds and mesogenic media
    Patent number: 10450508
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula l in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Kevin Adlem, Owain Llyr Parri, Rachel Tuffin, Hassan Arasi, Benjamin Snow
  • Materials for organic electroluminescent devices
    Patent number: 10454041
    Abstract: The present invention relates to a process to produce compounds of the formula (1) which are suitable for use in electronic devices, as well as to intermediate compounds of formula (Int-1) and compounds of formula (1-1) and (1-2) obtained via the process. These compounds are particularly suitable for use organic electroluminescent devices. The present invention also relate to electronic devices, which comprise these compounds.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro
  • Dengue virus vaccine compositions and methods of use thereof
    Patent number: 10449243
    Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3? untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 22, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Danilo R. Casimiro, Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
  • Antiviral oxime phosphoramide compounds
    Patent number: 10450335
    Abstract: Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 22, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wenlang Fu, Zhiqiang Guo, Ning Qi, Izzat T. Raheem, Petr Vachal, Ming Wang, John D. Schreier
  • Liquid crystal medium and liquid display
    Patent number: 10450509
    Abstract: Mesogenic media comprising one or more compounds of formulae I or II preferably mesogenic media showing a blue phase, preferably stabilized by a polymer, and their use in electro-optical light modulation elements and their respective use in displays, as well as such devices.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: October 22, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Wittek, Norihiko Tanaka, Malgorzata Rillich, Volker Reiffenrath, Axel Jansen
  • Materials for electronic devices
    Patent number: 10454040
    Abstract: The invention relates to a mixture containing at least two different triaryl amino compounds of formula (I). The mixture is suitable for use in an electronic device, preferably in an organic electroluminescent device, and in particular for use as a hole transport layer.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Frank Voges, Arne Buesing, Christof Pflumm, Teresa Mujica-Fernaud, Jonas V. Kroeber
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20190316037
    Abstract: The invention relates to a liquid-crystalline medium having negative dielectric anisotropy comprising one or more compounds of formula I and one or more compounds selected from the group of the compounds of the formulae IIA, IIB and IIC, wherein the groups and parameters have the meanings indicated in claim 1, to a guest-host liquid crystal medium derived therefrom comprising one or more dichroic dyes and the use of said medium in devices such as light shutters, switchable windows, switchable mirrors and guest-host displays. The invention further relates to devices containing the liquid crystalline medium according to the invention.
    Type: Application
    Filed: October 16, 2017
    Publication date: October 17, 2019
    Applicant: Merck Patent GmbH
    Inventors: Jung-Min LEE, Hyun-Woo BAE, Dong-Mee SONG, Yong-Kuk YUN